JP2009539457A - 医用材料 - Google Patents
医用材料 Download PDFInfo
- Publication number
- JP2009539457A JP2009539457A JP2009513765A JP2009513765A JP2009539457A JP 2009539457 A JP2009539457 A JP 2009539457A JP 2009513765 A JP2009513765 A JP 2009513765A JP 2009513765 A JP2009513765 A JP 2009513765A JP 2009539457 A JP2009539457 A JP 2009539457A
- Authority
- JP
- Japan
- Prior art keywords
- gadolinium
- medical material
- calcium
- calcium phosphate
- containing compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012567 medical material Substances 0.000 title claims abstract description 38
- 239000000463 material Substances 0.000 claims abstract description 84
- 229910052688 Gadolinium Inorganic materials 0.000 claims abstract description 72
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 62
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 56
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 51
- 229910000389 calcium phosphate Inorganic materials 0.000 claims abstract description 50
- 239000011575 calcium Substances 0.000 claims abstract description 34
- 229910004283 SiO 4 Inorganic materials 0.000 claims abstract description 29
- 239000000126 substance Substances 0.000 claims abstract description 7
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 60
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 56
- -1 gadolinium ions Chemical class 0.000 claims description 29
- 239000012071 phase Substances 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 28
- 210000000988 bone and bone Anatomy 0.000 claims description 26
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 22
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims description 19
- 229910052586 apatite Inorganic materials 0.000 claims description 18
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 17
- 229910052710 silicon Inorganic materials 0.000 claims description 17
- 239000010703 silicon Substances 0.000 claims description 17
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 claims description 14
- 239000002244 precipitate Substances 0.000 claims description 14
- 239000007943 implant Substances 0.000 claims description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 11
- 239000002210 silicon-based material Substances 0.000 claims description 10
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 8
- 238000002441 X-ray diffraction Methods 0.000 claims description 8
- 239000011574 phosphorus Substances 0.000 claims description 8
- 229910052698 phosphorus Inorganic materials 0.000 claims description 8
- 239000000316 bone substitute Substances 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 5
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 5
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 4
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 claims description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- UKOAOXYMPSILTM-UHFFFAOYSA-N gadolinium(3+);trisilicate Chemical compound [Gd+3].[Gd+3].[Gd+3].[Gd+3].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] UKOAOXYMPSILTM-UHFFFAOYSA-N 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 239000004254 Ammonium phosphate Substances 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 239000000908 ammonium hydroxide Substances 0.000 claims description 2
- 229910000148 ammonium phosphate Inorganic materials 0.000 claims description 2
- 235000019289 ammonium phosphates Nutrition 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- 239000000378 calcium silicate Substances 0.000 claims description 2
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 2
- JJIQGEZLLWXYKV-UHFFFAOYSA-N calcium;dinitrate;hydrate Chemical compound O.[Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O JJIQGEZLLWXYKV-UHFFFAOYSA-N 0.000 claims description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 2
- 239000004568 cement Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims description 2
- 150000002251 gadolinium compounds Chemical class 0.000 claims description 2
- MEANOSLIBWSCIT-UHFFFAOYSA-K gadolinium trichloride Chemical compound Cl[Gd](Cl)Cl MEANOSLIBWSCIT-UHFFFAOYSA-K 0.000 claims description 2
- MWFSXYMZCVAQCC-UHFFFAOYSA-N gadolinium(iii) nitrate Chemical compound [Gd+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O MWFSXYMZCVAQCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- JXJTWJYTKGINRZ-UHFFFAOYSA-J silicon(4+);tetraacetate Chemical compound [Si+4].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O JXJTWJYTKGINRZ-UHFFFAOYSA-J 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000002595 magnetic resonance imaging Methods 0.000 description 19
- 238000006467 substitution reaction Methods 0.000 description 17
- 238000003756 stirring Methods 0.000 description 15
- 239000000843 powder Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 239000000292 calcium oxide Substances 0.000 description 13
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 13
- 239000008367 deionised water Substances 0.000 description 13
- 229910021641 deionized water Inorganic materials 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 9
- 235000011114 ammonium hydroxide Nutrition 0.000 description 8
- 239000002872 contrast media Substances 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000002051 biphasic effect Effects 0.000 description 7
- 238000001816 cooling Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 238000005245 sintering Methods 0.000 description 3
- 239000002616 MRI contrast agent Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000012455 biphasic mixture Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000001027 hydrothermal synthesis Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- 238000003836 solid-state method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1803—Semi-solid preparations, e.g. ointments, gels, hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/10—Ceramics or glasses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/425—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B25/00—Phosphorus; Compounds thereof
- C01B25/16—Oxyacids of phosphorus; Salts thereof
- C01B25/26—Phosphates
- C01B25/32—Phosphates of magnesium, calcium, strontium, or barium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Engineering & Computer Science (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Ceramic Engineering (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Materials For Medical Uses (AREA)
Abstract
【選択図】 図1
Description
Ca10−yGdy(PO4)6−x(SiO4)x(OH)2−x+y
を有する化合物を含む。
(1) Gd3+ + SiO4 4− → Ca2+ + PO4 3−
となる。
Ca10−xGdx(PO4)6−x(SiO4)x(OH)2
によって要約できる。
(2) 0.5Gd3+ + SiO4 4− → 0.5Ca2+ + PO4 3− + 0.5OH−
となる。
Ca10−yGdy(PO4)6−x(SiO4)x(OH)2−x+y
(この機序において、y<xである)
によって要約できる。
Ca10−yGdy(PO4)6−x(SiO4)x(OH)2−x+y
式中、x=y=1.0
という置換機序を有する水性沈殿法による、約10gのGd3+/SiO4 4−共置換ヒドロキシアパタイトの合成について記述する。
Ca10−yGdy(PO4)6−x(SiO4)x(OH)2−x+y
式中、x=1.0、y=0.5
という置換機序を有する水性沈殿法による、約10gのGd3+/SiO4 4−共置換ヒドロキシアパタイトの合成について記述する。
Ca10−yGdy(PO4)6−x(SiO4)x(OH)2−x+y
式中、x=1.1、y=1.1
という置換機序を有する水性沈殿法による、約10gのGd3+/SiO4 4−共置換ヒドロキシアパタイト/リン酸三カルシウム二相性混合物の合成について記述する。
Claims (48)
- ガドリニウムを含む、合成のリン酸カルシウムベースの医用材料。
- 前記ガドリニウムの少なくとも一部が、前記リン酸カルシウム格子内で置換されGd3+イオンの形態である、請求項1に記載の医用材料。
- ケイ素及び/又はケイ酸塩をさらに含む、請求項1又は2に記載の医用材料。
- 前記リン酸カルシウムベースの医用材料がヒドロキシアパタイト又はアパタイトを含む、前記請求項のいずれか一項に記載の医用材料。
- 前記材料が一般化学式
Ca10−yGdy(PO4)6−x(SiO4)x(OH)2−x+y
を有し、式中、0<x<1.3且つ0<y<1.3である化合物を含む、前記請求項のいずれか一項に記載の医用材料。 - 0.5<x<1.1である、請求項5に記載の医用材料。
- 0.001<y<1.1である、請求項5又は6に記載の医用材料。
- 0.1<y<1.3である、請求項7に記載の医用材料。
- 0<y<0.001である、請求項5又は6に記載の医用材料。
- 好ましくは0<y<0.0005である、請求項9に記載の医用材料。
- x≧yである、請求項5〜10のいずれか一項に記載の医用材料。
- X線回折によって測定された、前記医用材料の相純度が95%以上、好ましくは97%以上、より好ましくは99%以上である、前記請求項のいずれか一項に記載の医用材料。
- 前記医用材料が1つ又は複数の二次相を含む、前記請求項のいずれか一項に記載の医用材料。
- 前記1つ又は複数の二次相が、リン酸三カルシウム、そのα若しくはβ同質異像体、ケイ酸カルシウム、又はリン酸四カルシウムを含む、請求項13に記載の医用材料。
- 前記ガドリニウムイオンが前記リン酸カルシウム格子内のカルシウムイオンを置換している、前記請求項のいずれか一項に記載の医用材料。
- 前記ケイ酸イオンが前記リン酸カルシウム格子内のリン酸イオンを置換している、請求項3〜15のいずれか一項に記載の医用材料。
- 合成のガドリニウム−ケイ酸塩共置換リン酸カルシウムベースの材料を含む医用材料。
- ガドリニウムを含有しない医用材料と混合した、請求項1〜17のいずれか一項に記載の医用材料。
- 請求項1〜18のいずれか一項に記載の医用材料を含む、合成骨材料、骨インプラント、骨移植片、骨代替物、骨足場、充填剤、コーティング、又はセメント。
- ガドリニウムと、任意選択でケイ素とを含む、リン酸カルシウムベースの材料を合成する方法であって、
カルシウム又はカルシウム含有化合物、ガドリニウム含有化合物、リン含有化合物、及び任意選択でケイ素含有化合物を用意するステップと、
前記化合物をアルカリ性pHの水相中で反応させることによって沈殿物を形成させるステップと
を含む方法。 - 前記リン酸カルシウムベースの材料がヒドロキシアパタイト又はアパタイトを含む、請求項20に記載の方法。
- 前記カルシウム含有化合物がカルシウム塩を含む、請求項20又は21に記載の方法。
- 前記カルシウム塩が、水酸化カルシウム、塩化カルシウム、硝酸カルシウム、及び/又は硝酸カルシウム水和物のうちの1つ又は複数から選択される、請求項22に記載の方法。
- 前記ガドリニウム含有化合物が、塩化ガドリニウム及び/又は硝酸ガドリニウムの一方又は両方から選択される、請求項20〜23のいずれか一項に記載の方法。
- 前記材料中にガドリニウムが最大13重量パーセントの量で存在する、請求項20〜24のいずれか一項に記載の方法。
- 前記材料中にガドリニウムが最大12重量パーセントの量で存在する、請求項25に記載の方法。
- 前記リン含有化合物がリン酸塩及び/又はリン酸の一方又は両方から選択される、請求項20〜26のいずれか一項に記載の方法。
- 前記リン含有化合物がリン酸アンモニウム及び/又はリン酸の一方又は両方から選択される、請求項27に記載の方法。
- 前記(任意選択の)ケイ素含有化合物がケイ酸塩を含む、請求項20〜28のいずれか一項に記載の方法。
- 前記ケイ酸塩がオルトケイ酸テトラエチル(TEOS)及び/又は酢酸ケイ素の一方又は両方から選択される、請求項29に記載の方法。
- 前記材料中に前記ケイ酸塩が最大13重量パーセント、好ましくは最大12重量パーセントの量で存在する、請求項29又は30に記載の方法。
- 前記pHが8〜13である、請求項20〜31のいずれか一項に記載の方法。
- 前記pHが10〜12である、請求項32に記載の方法。
- 前記溶液のpHを所望のpHに調整するためにアルカリを添加する、請求項20〜33のいずれか一項に記載の方法。
- 前記アルカリが水酸化アンモニウム又は濃アンモニアである、請求項34に記載の方法。
- 前記沈殿物が形成された後に、前記沈殿物を乾燥、加熱及び/又は焼結する、請求項20〜35のいずれか一項に記載の方法。
- 前記沈殿物を800℃から1500℃の範囲の温度まで加熱及び/又は焼結する、請求項36に記載の方法。
- 前記沈殿物を1000℃から1350℃、好ましくは1200℃から1300℃の範囲の温度まで加熱及び/又は焼結する、請求項37に記載の方法。
- 前記ケイ素含有化合物及び前記ガドリニウム含有化合物を、ケイ素の量及びガドリニウム陽イオンの量に換算して等モル量で供給する、請求項20〜38のいずれか一項に記載の方法。
- 前記ケイ素含有化合物を、ケイ素の量及びガドリニウム陽イオンの量に換算して、前記ガドリニウム化合物より多い量で供給する、請求項20〜38のいずれか一項に記載の方法。
- 前記リン酸カルシウムベースのガドリニウム含有材料を、ガドリニウムを含まない材料で希釈するステップをさらに含む、請求項20〜40のいずれか一項に記載の方法。
- 前記ガドリニウムを含まない材料がリン酸カルシウムベースの材料を含む、請求項41に記載の方法。
- 前記ガドリニウムを含まない材料が高分子材料を含む、請求項41に記載の方法。
- リン酸カルシウム材料のMRIコントラストを改善する方法であって、格子内にGd3+を置換導入するステップを含む方法。
- ケイ素置換リン酸カルシウム材料のMRIコントラストを改善する方法であって、格子内にGd3+を共置換導入するステップを含む方法。
- 前記リン酸カルシウム材料がヒドロキシアパタイト又はアパタイトを含む、請求項44又は45に記載の方法。
- MRIコントラストを改善するために合成ヒドロキシアパタイト格子又はアパタイト格子内に置換導入されたガドリニウムの使用。
- MRIコントラストを改善するために合成ヒドロキシアパタイト格子又はアパタイト格子内にケイ酸塩と共に共置換導入されたガドリニウムの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0611223A GB2442000A (en) | 2006-06-07 | 2006-06-07 | Biomedical materials containing gadolinium |
GB0611223.9 | 2006-06-07 | ||
PCT/GB2007/002116 WO2007141537A1 (en) | 2006-06-07 | 2007-06-07 | Biomedical materials |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009539457A true JP2009539457A (ja) | 2009-11-19 |
JP5577536B2 JP5577536B2 (ja) | 2014-08-27 |
Family
ID=36745411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009513765A Active JP5577536B2 (ja) | 2006-06-07 | 2007-06-07 | 医用材料 |
Country Status (7)
Country | Link |
---|---|
US (3) | US9561960B2 (ja) |
EP (1) | EP2029481B1 (ja) |
JP (1) | JP5577536B2 (ja) |
AU (1) | AU2007255200B2 (ja) |
ES (1) | ES2692167T3 (ja) |
GB (1) | GB2442000A (ja) |
WO (1) | WO2007141537A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017148553A (ja) * | 2008-01-09 | 2017-08-31 | ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・アバディーン | バイオセラミック組成物の合成 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101549161B (zh) * | 2009-05-13 | 2010-12-01 | 中南大学 | 一种肝、脾脏特异性阳性核磁共振对比剂及其制备方法 |
US9492590B2 (en) | 2010-04-16 | 2016-11-15 | Apatech Limited | Biomaterial |
EP3114080B1 (en) * | 2014-03-03 | 2021-08-25 | Bio-Rad Laboratories, Inc. | Methods for producing a hydroxyapatite composition |
CN108713056B (zh) | 2016-03-02 | 2020-12-18 | 荷兰联合利华有限公司 | 悬浮液形式的洗涤剂组合物 |
AR107756A1 (es) | 2016-03-02 | 2018-05-30 | Unilever Nv | Composición detergente fluida y procedimiento para prepararla |
CN107412790B (zh) * | 2017-09-08 | 2019-02-22 | 丽水市中心医院 | 一种核磁共振纳米材料的制备方法 |
CN111320847A (zh) * | 2020-03-31 | 2020-06-23 | 扬州大学 | 一种3d打印医用复合材料骨板的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08509217A (ja) * | 1993-04-13 | 1996-10-01 | マリンクロット・メディカル・インコーポレイテッド | 医療診断イメージング用の処理されたカルシウム/オキシアニオン含有粒子 |
JPH11501839A (ja) * | 1995-03-09 | 1999-02-16 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | 外科医術用および治療用超音波を集中させる磁気共鳴法 |
JP2000517281A (ja) * | 1996-08-30 | 2000-12-26 | アボネティックス・リミテッド | 珪素置換アパタイトおよびその製法 |
JP2007197329A (ja) * | 2006-01-23 | 2007-08-09 | Kuraray Medical Inc | リン酸カルシウム組成物及びその製造方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2751939C3 (de) * | 1976-11-22 | 1979-07-12 | Tokyo Shibaura Electric Co., Ltd., Kawasaki, Kanagawa (Japan) | Gadolinium-aktivierter Phosphatleuchtstoff |
US5137709A (en) * | 1991-02-15 | 1992-08-11 | The Dow Chemical Company | Layered mixed metal hydroxides for the stabilization of radioactive colloids |
US5344640A (en) * | 1991-10-22 | 1994-09-06 | Mallinckrodt Medical, Inc. | Preparation of apatite particles for medical diagnostic imaging |
US5520904A (en) * | 1995-01-27 | 1996-05-28 | Mallinckrodt Medical, Inc. | Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging |
FR2784091B1 (fr) * | 1998-09-11 | 2000-11-10 | Commissariat Energie Atomique | Procede pour confiner le plutonium dans des ceramiques apatitiques et produits obtenus par ce procede |
EP1280732B1 (fr) * | 2000-04-26 | 2004-06-02 | Ecole Polytechnique Fédérale de Lausanne | Microgranules phosphocalciques |
DE20218668U1 (de) * | 2002-12-03 | 2003-03-06 | Sanatis Gmbh | Rezepturen für Zementzubereitungen als Knochenersatz |
US20050287071A1 (en) * | 2002-12-03 | 2005-12-29 | Kyphon Inc. | Formulation for a cement preparation as bone substitute |
CN1942396B (zh) * | 2004-03-15 | 2010-09-01 | 苏黎世联合高等工业学校 | 金属盐纳米颗粒,特别是包含钙和磷酸根的纳米颗粒的火焰合成 |
SE528360C2 (sv) * | 2004-09-10 | 2006-10-24 | Doxa Ab | Resorberbara keramiska kompositioner avsedda för medicinska implantat |
US7695740B2 (en) * | 2005-06-29 | 2010-04-13 | Iain Ronald Gibson | Synthetic calcium phosphate comprising silicon and trivalent cation |
-
2006
- 2006-06-07 GB GB0611223A patent/GB2442000A/en not_active Withdrawn
-
2007
- 2007-06-07 AU AU2007255200A patent/AU2007255200B2/en active Active
- 2007-06-07 JP JP2009513765A patent/JP5577536B2/ja active Active
- 2007-06-07 ES ES07733127.0T patent/ES2692167T3/es active Active
- 2007-06-07 US US12/303,951 patent/US9561960B2/en active Active
- 2007-06-07 WO PCT/GB2007/002116 patent/WO2007141537A1/en active Application Filing
- 2007-06-07 EP EP07733127.0A patent/EP2029481B1/en active Active
-
2017
- 2017-01-27 US US15/418,304 patent/US10532114B2/en active Active
-
2020
- 2020-01-08 US US16/737,409 patent/US10967075B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08509217A (ja) * | 1993-04-13 | 1996-10-01 | マリンクロット・メディカル・インコーポレイテッド | 医療診断イメージング用の処理されたカルシウム/オキシアニオン含有粒子 |
JPH11501839A (ja) * | 1995-03-09 | 1999-02-16 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | 外科医術用および治療用超音波を集中させる磁気共鳴法 |
JP2000517281A (ja) * | 1996-08-30 | 2000-12-26 | アボネティックス・リミテッド | 珪素置換アパタイトおよびその製法 |
JP2007197329A (ja) * | 2006-01-23 | 2007-08-09 | Kuraray Medical Inc | リン酸カルシウム組成物及びその製造方法 |
Non-Patent Citations (2)
Title |
---|
JPN6012050206; Kouichi Nakashima et al.: 'Magnetic properties of gadolinium-doped beta-tricalcium phosphate' Journal of Alloys and Compounds Volumes 408-412, 200602, 761-765 * |
JPN6012050209; 川尻哲夫: '希土類元素を含むアパタイトの人工歯根材料への応用に関する基礎的化学的研究' 歯科医学 巻:51 号:1, 19880225, 頁:75-96 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017148553A (ja) * | 2008-01-09 | 2017-08-31 | ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・アバディーン | バイオセラミック組成物の合成 |
Also Published As
Publication number | Publication date |
---|---|
US10532114B2 (en) | 2020-01-14 |
US10967075B2 (en) | 2021-04-06 |
AU2007255200A1 (en) | 2007-12-13 |
WO2007141537A1 (en) | 2007-12-13 |
US20200138981A1 (en) | 2020-05-07 |
GB2442000A (en) | 2008-03-26 |
EP2029481A1 (en) | 2009-03-04 |
AU2007255200B2 (en) | 2013-11-21 |
US20100322867A1 (en) | 2010-12-23 |
US20170136133A1 (en) | 2017-05-18 |
EP2029481B1 (en) | 2018-10-03 |
GB0611223D0 (en) | 2006-07-19 |
ES2692167T3 (es) | 2018-11-30 |
US9561960B2 (en) | 2017-02-07 |
JP5577536B2 (ja) | 2014-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10967075B2 (en) | Biomedical materials | |
JP5128472B2 (ja) | 医用材料 | |
CA1332495C (en) | In situ calcium phosphate minerals -- method and composition | |
US6495156B2 (en) | Biocements having improved compressive strength | |
US5047031A (en) | In situ calcium phosphate minerals method | |
Kannan et al. | Aqueous precipitation method for the formation of Mg-stabilized β-tricalcium phosphate: An X-ray diffraction study | |
EP2403544B1 (en) | Galliated calcium phosphate biomaterials | |
Eichert et al. | Nanocrystalline apatite-based biomaterials: synthesis, processing and characterization | |
Putlyaev et al. | A new generation of calcium phosphate biomaterials: the role of phase and chemical compositions | |
JP5280403B2 (ja) | リン酸カルシウム骨セメント、その前駆体およびその作製方法 | |
JP2017148553A (ja) | バイオセラミック組成物の合成 | |
US20190192725A1 (en) | Magnesium phosphate biomaterials | |
US8894958B2 (en) | Galliated calcium phosphate biomaterials | |
EP3731886B1 (en) | Production of beta-tri-calcium phosphate (beta-tcp) with high purity | |
Elliott | Formation of Fluoridated Hydroxyapatite by Competitive Attack of OH-and F-ions onto. ALPHA.-or. BETA.-Tricalcium Bis (Orthophosphate) | |
Kent | Development of a Novel In-vivo Setting Bone Graft Substitute From Bioactive Glass | |
Nor et al. | Synthesis of Tricalcium Phosphate at Different pH Condition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100603 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120925 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121221 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130125 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130402 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130618 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130625 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130731 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130807 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130830 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140114 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140410 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140417 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140509 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140610 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140618 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5577536 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |